Predicting Treatment Response and the Role of the ISG15/USP18 Ubiquitin-like Signaling Pathway in Hepatitis C Viral Infection
Hepatitis C Virus (HCV) infects 170 million people worldwide. The current treatment regimen, which is combination therapy with pegylated interferon (PegIFN) and Ribavirin (Rib), cures only 50% of the patients infected with the most prevalent HCV genotype. Therefore, there is a pressing need to unde...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/26137 |